Li Xue, Feng Hua, Jian Hengheng, Zhang Shilan, Tai Zhaoli Liao, Wang Xiaoyu, Lu Fengzhi, Liu Zuwei, Li Tingchao, Ji Yangsong, Liu Youxuan, Ma Zuxia
Department of Otorhinolaryngology, The Third Affiliated Hospital of ZunYi Medical University/First People's Hospital of Zunyi, Zunyi, China.
Mol Carcinog. 2025 Apr;64(4):629-637. doi: 10.1002/mc.23872. Epub 2025 Jan 8.
This study aimed to explore PTPN2 expression levels in Hypopharyngeal Squamous Cell Carcinoma (HPSCC) tissues and their relationship with the clinical characteristics and prognosis of HPSCC patients. PTPN2, a protein tyrosine phosphatase, has recently emerged as a promising target for cancer immunotherapy, and in many previous studies, PTPN2 may have a significant role in the growth, differentiation, metabolism and immune response of head and neck malignant tumors. In this study, PTPN2 expression in Head and Neck Squamous Cell Carcinoma (HNSCC) and other cancer tissues was analyzed using datasets derived from the Sangerbox database. Furthermore, we analyzed data on PTPN2 mRNA levels across various clinical stages of HNSCC (I, II, III, and IV), which was extracted from the Gene Expression Profiling Interactive Analysis (GEPIA) database. Clinical data from patients who underwent surgical resection for hypopharyngeal malignancies at the Third Affiliated Hospital of Zunyi Medical University between January 2013 and January 2024 were also obtained and analyzed. The patient specimens were categorized into two groups (the HPSCC tumor and paracarcinoma tissue groups) and compared for PTPN2 expression using Immunohistochemistry (IHC), Immunofluorescence (IF), and Western Blot (WB) analyses. According to the results, HPSCC patients were mostly elderly males with a history of tobacco and alcohol abuse. Furthermore, the most common site of HPSCC onset was piriform sinuses, and the disease was often diagnosed in the middle or advanced stages. Additionally, HPSCC tissues exhibited PTPN2 upregulation. Moreover, PTPN2 expression did not correlate significantly with patients' gender, Smoking Index (SI), alcohol abuse, tumor diameter, Hypertension (HTN), diabetes, and M stage. On the other hand, it correlated with HPSCC patients' T-stage, N-stage, Overall Survival (OS), and clinical stage. Based on these findings, we deduced that high PTPN2 expression could be involved in HPSCC patients' poor prognosis.
本研究旨在探讨下咽鳞状细胞癌（HPSCC）组织中蛋白酪氨酸磷酸酶非受体型2（PTPN2）的表达水平及其与HPSCC患者临床特征和预后的关系。PTPN2是一种蛋白酪氨酸磷酸酶，最近已成为癌症免疫治疗的一个有前景的靶点，并且在许多先前的研究中，PTPN2可能在头颈部恶性肿瘤的生长、分化、代谢和免疫反应中发挥重要作用。在本研究中，使用来自Sangerbox数据库的数据集分析了头颈部鳞状细胞癌（HNSCC）和其他癌组织中PTPN2的表达。此外，我们分析了从基因表达谱交互分析（GEPIA）数据库中提取的HNSCC各临床分期（I、II、III和IV期）的PTPN2 mRNA水平数据。还获取并分析了2013年1月至2024年1月期间在遵义医科大学第三附属医院接受下咽恶性肿瘤手术切除患者的临床数据。将患者标本分为两组（HPSCC肿瘤组织和癌旁组织组），并使用免疫组织化学（IHC）、免疫荧光（IF）和蛋白质免疫印迹（WB）分析比较PTPN2的表达。结果显示，HPSCC患者多为老年男性，有烟酒滥用史。此外，HPSCC最常见的发病部位是梨状窝，且该病常于中晚期被诊断出来。另外，HPSCC组织呈现PTPN2上调。而且，PTPN2表达与患者的性别、吸烟指数（SI）、酗酒、肿瘤直径、高血压（HTN）、糖尿病和M分期无显著相关性。另一方面，它与HPSCC患者的T分期、N分期、总生存期（OS）和临床分期相关。基于这些发现，我们推断PTPN2高表达可能与HPSCC患者的不良预后有关。
